Machine-learning algorithm for predicting stone recurrence shows promise

The median radiographic progression-free survival with FG-3246 in mCRPC was 8.7 months.

Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.

The conference explored the current and future use of PSMA-PET imaging and PSMA radioligand therapy to improve the clinical care of patients with prostate cancer.

Adam B. Weiner, MD, and Ruchika Talwar, MD, discuss some of the notable urologic oncology abstracts that were presented at the 2023 AUA meeting.

Data revealed that 49% of prostate cancer signups in clinical trials were among patients newly diagnosed with cancer, compared with 32% among patients with other solid tumors.

“Our study provides real-world recurrence and survival rates, [however], a major limitation is the retrospective nature of the analysis,” wrote the investigators, led by Viktor Gruenwald, MD, PhD.